{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sakr SM"],"funding":["Abbott Laboratories","NIH HHS"],"pagination":["450-459"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12925993"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["49(3)"],"pubmed_abstract":["<h4>Objective</h4>Type 2 diabetes (T2D) is a significant risk factor for adverse outcomes in coronary heart disease (CHD). We investigated whether inflammation and immune dysregulation, measured using soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein (hs-CRP) levels, mediate this risk.<h4>Research design and methods</h4>Patients with and without CHD enrolled in the Emory Cardiovascular Biobank had suPAR (ViroGates, Denmark) and hs-CRP levels measured and were followed for 1) cardiovascular death, 2) a composite of incident myocardial infarction and cardiovascular death, and 3) all-cause death. Fine and Gray or Cox proportional hazards models adjusted for demographic, clinical, and treatment variables were used. Regression-based causal mediatio"],"journal":["Diabetes care"],"pubmed_title":["Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease."],"pmcid":["PMC12925993"],"funding_grant_id":["3R01HL157311-03S1","P01HL154996-01A1","5T32 HL130025","P30DK111024-07S2","R01HL166004-01","5R01HL158141-043","1R01HL166004-01","R33HL138657-05"],"pubmed_authors":["Lodhi R","Eldaidamouni AA","Ahmed T","Huang J","Sakr SM","Pasquel FJ","Medina-Inojosa J","Quyyumi AA","Yadalam AK","Ali MK","Desai S","Harris KA","Yeboah R","Haroun N","Razavi AC","Owais M","Ko YA","Mohan V","Tandon N","Al Kasem M","Liu C","Narayan KMV","Hartsfield JD"],"additional_accession":[]},"is_claimable":false,"name":"Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease.","description":"<h4>Objective</h4>Type 2 diabetes (T2D) is a significant risk factor for adverse outcomes in coronary heart disease (CHD). We investigated whether inflammation and immune dysregulation, measured using soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein (hs-CRP) levels, mediate this risk.<h4>Research design and methods</h4>Patients with and without CHD enrolled in the Emory Cardiovascular Biobank had suPAR (ViroGates, Denmark) and hs-CRP levels measured and were followed for 1) cardiovascular death, 2) a composite of incident myocardial infarction and cardiovascular death, and 3) all-cause death. Fine and Gray or Cox proportional hazards models adjusted for demographic, clinical, and treatment variables were used. Regression-based causal mediatio","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-16T18:34:02.445Z","creation":"2026-07-11T03:08:33.4Z"},"accession":"S-EPMC12925993","cross_references":{"pubmed":["41533335"],"doi":["10.2337/dc25-0940"]}}